Nuclide Tx named start-up to watch in 2026

Nuclide Therapeutics has today been named one of Chemical & Engineering News (C&EN)’s 10 start-ups to watch in 2026.

C&EN’s Laurel Oldach spoke with co-founders Dr Muhammet Tanc (CEO) and Professor Tim Witney (CSO) about the company’s approach to radiotheranostic development and what sets Nuclide apart in the radiopharmaceutical landscape.

Read the full feature and explore C&EN’s 10 start-ups to watch in 2026.